KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

被引：0

作者：

Schmid, P. ^{[1
]}

Cortes, J. ^{[2
,3
,4
]}

Dent, R. ^{[5
]}

Pusztai, L. ^{[6
]}

McArthur, H. L. ^{[7
]}

Kuemmel, S. ^{[8
]}

Bergh, J. ^{[9
,10
]}

Denkert, C. ^{[11
]}

Park, Y. H. ^{[12
]}

Hui, R. ^{[13
,14
]}

Harbeck, N. ^{[15
]}

Takahashi, M. ^{[16
]}

Foukakis, T. ^{[9
,10
]}

Fasching, P. A. ^{[17
]}

Cardoso, F. ^{[18
]}

Jia, L. ^{[19
]}

Karantza, V. ^{[20
]}

Zhao, J. ^{[21
]}

Aktan, G. ^{[20
]}

O'Shaughnessy, J. ^{[22
]}

机构：

[1] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England

[2] IOB Inst Oncol, Quironsalud Grp, Oncol Dept, Madrid, Spain

[3] IOB Inst Oncol, Quironsalud Grp, Oncol Dept, Barcelona, Spain

[4] Vall dHebron Intitute Oncol VHIO, Barcelona, Spain

[5] Univ Toronto, Toronto, ON, Canada

[6] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA

[7] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA

[8] Kliniken Essen Mitte Evang, Breast Unit, Essen, Germany

[9] Karolinska Inst, Dept Oncol Pathol, Solna, Sweden

[10] Karolinska Univ Hosp, Breast Canc Ctr, Canc Theme, Solna, Sweden

[11] Philipps Univ Marburg, Inst Pathol, Marburg, Germany

[12] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Hematol Oncol, Seoul, South Korea

[13] Westmead Hosp, Dept Med Oncol, Sydney, NSW, Australia

[14] Univ Sydney, Sydney, NSW, Australia

[15] Univ Munich LMU, Breast Ctr, Dept Gynecol & Obstet, Munich, Germany

[16] NKO Hokkaido Canc Ctr, Dept Breast Surg, Sapporo, Hokkaido, Japan

[17] Friedrich Alexander Univ Erlangen Nuremberg, Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN, Gynecol & Obstet, Erlangen, Germany

[18] Champalimaud Fdn, Breast Unit, Canc Ctr, Lisbon, Portugal

[19] Merck & Co Inc, Biostat, Kenilworth, NJ USA

[20] Merck & Co Inc, Dept Oncol, Kenilworth, NJ USA

[21] Merck & Co Inc, Biostat, N Wales, PA USA

[22] Baylor Univ, Med Ctr, Breast Oncol, Dallas, TX USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA8_PR

引用

页码：853 / 854

页数：2

共 50 条

[41] Real-world comparison: Neoadjuvant pembrolizumab (pembro-NACT) vs. dose-dense neoadjuvant chemotherapy (ddNACT) in early stage triple-negative breast cancer (TNBC)
Barbi, Mali
Noel, Jovanka
Lee, Chung-Shien
Rahman, Husneara
Cheng, Kit
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[42] KEYNOTE-585: randomized, phase 3 study of chemotherapy plus pembrolizumab vs chemotherapy plus placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer
Bang, Yung-Jue
Van Cutsem, Eric
Fuchs, Charles
Ohtsu, Atsushi
Tabernero, Josep
Ilson, David
Hyung, Woo Jin
Strong, Vivian
Goetze, Thorsten
Yoshikawa, Takaki
Tang, Laura
Sun, Linda
Hasan, Aisha
Koshiji, Minori
Shitara, Kohei
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[43] KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib (ola) vs pembro plus chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
Saji, S.
Cussac, A. Llombart
Andre, F.
Robson, M. E.
Harbeck, N.
Schmid, P.
Cescon, D. W.
Ahn, J. S.
Nanda, R.
Fan, L.
Mejia, J. A.
Karantza, V.
Bardia, A.
Rugo, H. S.
ANNALS OF ONCOLOGY, 2020, 31 : S1268 - S1268
[44] CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage IIeIIIb NSCLC
Cascone, T.
Awad, M. M.
Spicer, J. D.
He, J.
Lu, S.
Sepesi, B.
Tanaka, F.
Taube, J. M.
Cornelissen, R.
Havel, L.
Kuzdzal, J.
Petruzelka, L. B.
Wu, L.
Pujol, J. L.
Ito, H.
Erdmann, C. Coronado
Sathyanarayana, P.
Meadows-Shropshire, S.
Pulla, M. Provencio
ANNALS OF ONCOLOGY, 2023, 34 : S1295 - S1295
[45] Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis
Cortes, J.
Haiderali, A.
Huang, M.
Pan, W.
Fox, G. E.
Park, J.
Frederickson, A. M.
Fasching, P. A.
O'Shaughnessy, J.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S615 - S616
[46] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
Cortes, Javier
Guo, Zifang
Karantza, Vassiliki
Aktan, Gursel
CANCER RESEARCH, 2017, 77
[47] A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).
Tolaney, Sara M.
Kalinsky, Kevin
Kaklamani, Virginia G.
D'Adamo, David R.
Aktan, Gursel
Tsai, Michaela L.
O'Regan, Ruth
Kaufman, Peter A.
Wilks, Sharon
Andreopoulou, Eleni
Patt, Debra A.
Yuan, Yuan
Wang, Grace
Xing, Dongyuan
Kleynerman, Ella
Karantza, Vassiliki
Diab, Sami
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[48] Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
Rha, S. Y.
Wyrwicz, L. S.
Weber, P. E. Y.
Bai, Y.
Ryu, M. H.
Lee, J.
Rivera, F.
Alves, G. V.
Garrido, M.
Shiu, K. -k.
Fernandez, M. Gonzalez
Li, J.
Lowery, M.
Cil, T.
Cruz, F. J. S. M.
Qin, S.
Yin, L.
Bordia, S.
Bhagia, P.
Oh, D-y.
ANNALS OF ONCOLOGY, 2023, 34 (03) : 319 - 320
[49] Safety evaluation from the KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer
Rugo, Hope
Schmid, Peter
Nowecki, Zbigniew
Cescon, David
Im, Seock-Ah
Yusof, Mastura
Gallardo, Carlos
Iwata, Hiroji
Barrios, Carlos
Loi, Sherene
Zhou, Xuan
Zhang, Xiaoli
Pan, Wilbur
Karantza, Vassiliki
Cortes, Javier
CANCER RESEARCH, 2024, 84 (09)
[50] KEYNOTE-866: Phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC)
Siefker-Radtke, A. O.
Steinberg, G.
Bedke, J.
Nishiyama, H.
Martin, J.
Kataria, R.
Frenkl, T. L.
Hoimes, C. J.
ANNALS OF ONCOLOGY, 2019, 30 : 401 - 401

← 1 2 3 4 5 →